Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabigatran Etexilate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 19/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.76 |
| ▸ | NQO2 | P16083 | 2/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 1/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.62 |
| ▸ | PLAT | P00750 | 1/20 | 0.62 |
| ▸ | PROC | P04070 | 1/20 | 0.62 |
| ▸ | HPN | P05981 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.62 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.62 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781620 | 0.99 | F2 (0.77) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL505829 | 0.99 | F2 (0.77) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL3576423 | 0.99 | F2 (0.76) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL6517210 | 0.99 | F2 (0.76) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL1268805 | 0.97 | F2 (0.74) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL2525835 | 0.96 | F2 (0.73) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| Dabigatran Etexilate SCHEMBL2525834 | 0.96 | F2 (0.73) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| SCHEMBL6775505 | 0.95 | F2 (0.70) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| SCHEMBL6781399 | 0.95 | F2 (0.70) | F2NR1I2ADORA3SLC6A2AGTR1 | |
| SCHEMBL6781408 | 0.95 | F2 (0.70) | F2NR1I2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042948-A1 | Physiologically acceptable salts of 3--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | US | claimed |
| US-20060247278-A1 | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247278-A1 | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | SLC16A3, SLC16A8, SLC16A1 | F2 795/4885NR1I2 1315/4885ADORA3 510/4885 |
| US-20090042948-A1 | Physiologically acceptable salts of 3--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | SLC16A8, SLC16A1, SLC16A3 | F2 620/4885NR1I2 1101/4885ADORA3 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.